New data on Ocrevus broadens understanding of MS

Genentech announced new clinical and real-world data on its anti-CD20 therapy Ocrevus (ocrelizumab) at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis) that it said “continue to deepen our understanding of multiple sclerosis (MS).”

Ocrevus is the first and only therapy approved for both relapsing forms of MS (RMS) (including relapsing-remitting MS [RRMS] and active, or relapsing secondary progressive MS [SPMS]), in addition to clinically isolated syndrome [CIS] in the US) and primary progressive MS (PPMS), says Genentech, the US biotech subsidiary of Swiss pharma giant Roche (ROG: SIX).

Key findings include: